Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical Business ReviewThe IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA points to liver injury with Amgen’s TavneosNext: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
